Therapies that enhance the expression of tumor suppressor genes such as p53, p16INK4a, p14ARF and p21CIP1, accompanied by at least one pluripotency factor (OCT4 or SOX2) used with a plasmid-delivery system to target cancer cells, seem more advantageous. This evidence concerns the gene TP53 and cancer.